在动脉样硬化心血管疾病中的聚合诱导发射光源的最新进展
Yue Lan1, Sheng'e Su1, Jiageng Cai2
1The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, 100191, China.
Advanced healthcare materials
|September 4, 2025
概括
聚合诱导的发光剂 (AIEgens) 在诊断和治疗动脉样硬化心血管疾病 (ASCVD) 中具有前景. 本综述强调了AIEgen在ASCVD传感,成像和治疗中的特性和应用.
科学领域:
- * 纳米技术和材料科学
- * 生物医学工程
- * 药物化学
背景情况:
- * 动脉样性心血管疾病 (ASCVD) 是全球主要的死亡原因.
- * 斑块的形成涉及动脉壁中的脂质积累,导致严重的并发症.
- 新的诊断和治疗药物对于治疗ASCVD至关重要.
研究的目的:
- * 对ASCVD的聚合诱导排放光原体 (AIEgens) 的最新进展进行审查.
- * 探索AIEgen属性及其用于ASCVD管理的设计.
- * 总结AIEgen在ASCVD生物标志物传感,成像和治疗中的应用.
主要方法:
- *对ASCVD的AIEgen研究进行系统的文献审查 (过去五年).
- *对AIEgen特性进行分析:光,光稳定性,生物相容性.
- * 对AIEgen在传感,成像和治疗中的应用进行评估.
主要成果:
- * AIEgens在聚合状态下表现出增强的光,非常适合生物医学应用.
- * 量身定制的AIEgen设计可促进有效的ASCVD生物标志物检测和成像.
- * AIE基因在ASCVD治疗策略中表现出潜力.
结论:
- * AIEgens是ASCVD诊断和治疗的一类有前途的材料.
- 需要进一步的研究来应对当前的挑战,并优化AIEgen的效用.
- * 未来的前景包括加强AIEgen的开发以全面管理ASCVD.
更多相关视频
相关概念视频
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...